Scots-Knight Denise has filed 15 insider transactions across 2 companies since January 2024.
Most recent transaction: a grant/award of 480000 shares of Mereo BioPharma Group plc ($MREO) on February 01, 2026.
Activity breakdown: 0 open-market purchases and 4 sales.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 1, 2026 | Mereo BioPharma Group plc | $MREO | Scots-Knight Denise | Chief Executive Officer | A | Share Options (Right to buy) | 480000 | $0.00 | 480,000.0000 | 799,947,013 | 9999.99% | 0.06% |
| Feb. 1, 2026 | Mereo BioPharma Group plc | $MREO | Scots-Knight Denise | Chief Executive Officer | A | Share Options (Right to buy) | 345000 | $0.00 | 345,000.0000 | 799,947,013 | 9999.99% | 0.04% |
| Feb. 1, 2026 | Mereo BioPharma Group plc | $MREO | Scots-Knight Denise | Chief Executive Officer | A | Share Options (Right to buy) | 1035000 | $0.00 | 1,035,000.0000 | 799,947,013 | 9999.99% | 0.13% |
| Nov. 28, 2025 | Elanco Animal Health Inc | $ELAN | Scots-Knight Denise | Not found | A | Common Stock | 10314 | $0.00 | 88,714.0000 | 501,200,000 | 13.16% | 0.00% |
| Jan. 25, 2025 | Mereo BioPharma Group plc | $MREO | Scots-Knight Denise | Chief Executive Officer | A | Share Options (Right to buy) | 825000 | $0.00 | 825,000.0000 | 739,624,264 | 9999.99% | 0.11% |
| Nov. 29, 2024 | Elanco Animal Health Inc | $ELAN | Scots-Knight Denise | Not found | A | Common Stock | 18169 | $0.00 | 78,400.0000 | 497,700,000 | 30.17% | 0.00% |
| Sept. 12, 2024 | Mereo BioPharma Group plc | $MREO | Scots-Knight Denise | Chief Executive Officer | S | American Depositary Shares representing Ordinary Shares | 28611 | $4.47 | 868,967.0000 | 770,146,589 | 3.19% | 0.00% |
| Sept. 13, 2024 | Mereo BioPharma Group plc | $MREO | Scots-Knight Denise | Chief Executive Officer | S | American Depositary Shares representing Ordinary Shares | 60046 | $4.22 | 808,921.0000 | 770,146,589 | 6.91% | 0.01% |
| Sept. 11, 2024 | Mereo BioPharma Group plc | $MREO | Scots-Knight Denise | Chief Executive Officer | M | American Depositary Shares representing Ordinary Shares | 188060 | $0.00 | 897,578.0000 | 770,146,589 | 26.51% | 0.02% |
| Sept. 11, 2024 | Mereo BioPharma Group plc | $MREO | Scots-Knight Denise | Chief Executive Officer | M | Performance Based Restricted Stock Unit | 188060 | $0.00 | 0.0000 | 770,146,589 | 100.00% | 0.02% |
| June 25, 2024 | Mereo BioPharma Group plc | $MREO | Scots-Knight Denise | Chief Executive Officer | S | American Depositary Shares representing Ordinary Shares | 40712 | $3.69 | 801,791.0000 | 659,453,921 | 4.83% | 0.01% |
| June 26, 2024 | Mereo BioPharma Group plc | $MREO | Scots-Knight Denise | Chief Executive Officer | S | American Depositary Shares representing Ordinary Shares | 92273 | $3.39 | 709,518.0000 | 659,453,921 | 11.51% | 0.01% |
| June 21, 2024 | Mereo BioPharma Group plc | $MREO | Scots-Knight Denise | Chief Executive Officer | M | Performance Based Restricted Stock Unit | 282090 | $0.00 | 188,060.0000 | 659,453,921 | 0.00% | 0.04% |
| June 21, 2024 | Mereo BioPharma Group plc | $MREO | Scots-Knight Denise | Chief Executive Officer | M | American Depositary Shares representing Ordinary Shares | 282090 | $0.00 | 842,503.0000 | 659,453,921 | 50.34% | 0.04% |
| Jan. 25, 2024 | Mereo BioPharma Group plc | $MREO | Scots-Knight Denise | Chief Executive Officer | A | Share Options (Right to buy) | 850000 | $0.00 | 850,000.0000 | 659,453,921 | 9999.99% | 0.13% |